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Abstract
We develop a prediction-based prescriptive model for learning optimal personal-
ized treatments for patients based on their Electronic Health Records (EHRs). Our
approach consists of: (i) predicting future outcomes under each possible therapy
using a robustified nonlinear model, and (ii) adopting a randomized prescriptive
policy determined by the predicted outcomes. We show theoretical results that
guarantee the out-of-sample predictive power of the model, and prove the optimal-
ity of the randomized strategy in terms of the expected true future outcome. We ap-
ply the proposed methodology to develop optimal therapies for patients with type
2 diabetes or hypertension using EHRs from a major safety-net hospital in New
England, and show that our algorithm leads to a larger reduction of the HbA1c, for
diabetics, or systolic blood pressure, for patients with hypertension, compared to
the alternatives. We demonstrate that our approach outperforms the standard of
care under the robustified nonlinear predictive model.
1 Introduction
Learning the optimal treatment policies from large amounts of clinical data presents challenges due
to (i) the significant “noise” caused by recording errors, missing values, and large variability across
patients, (ii) the lack of counterfactual information, and (iii) the underlying nonlinearity whose
parametric form is not known a priori. Attempts on handling these issues have been focusing on
denoising [2, 16] and robust nonlinear learning [24, 15]. A popular research direction adopts a
dynamic point of view and models the optimal treatment problem through reinforcement learning
[4, 18, 13, 14] and A-learning [12, 15]. There are also works adopting a Bayesian approach [10, 21],
deep learning [2, 11], and miscellaneous statistical inference/machine learning methods [19, 17, 23,
22, 7] for constructing effective prescriptive rules.
We are interested in learning optimal treatment decisions from Electronic Health Records (EHRs)
using computationally efficient and interpretable predictive algorithms that address the aforemen-
tioned challenges. We start with a regularized Least Absolute Deviation (LAD) [20] model that is
obtained as a result of a Distributionally Robust Optimization (DRO) [5] problem and thus hedges
against significant noise and the presence of outliers. We then predict future outcomes under each
treatment by identifying neighbors through an LAD-weighted metric and fitting a K-Nearest Neigh-
bors (K-NN) regression model [1] that captures the local nonlinearity in a non-parametric way. A
randomized policy is then developed to prescribe each therapy with a probability inversely propor-
tional to its exponentiated predicted outcome.
Our method is similar to [3] where the K-NN regression with an Ordinary Least Squares (OLS)-
weighted metric was used to learn the optimal treatment for type 2 diabetic patients. The key dif-
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ferences lie in that: (i) we adopt a robustified regression procedure that is immunized against high
noise and is thus more stable and reliable; (ii) we propose a randomized prescriptive policy that
adds robustness to the methodology whereas [3] deterministically prescribed the treatment that was
predicted to result in the lowest HbA1c; (iii) we show rigorous theoretical results that guarantee the
optimality of the randomized strategy, and (iv) the prescriptive rule in [3] was activated when the
improvement of the recommended treatment over the standard of care exceeded a certain thresh-
old whereas our method looks into the improvement over the previous regimen. This distinction
makes our algorithm applicable in the scenario where the standard of care is unknown or ambigu-
ous. Further, we derive a closed-form expression for the threshold level, which greatly improves the
computational efficiency compared to [3] where a threshold was selected by cross-validation.
2 Methods
Given a training set of EHRs, we group the patients based on the treatment they receive at the time
of the visit. Within each treatment groupm ∈ [M ], where [M ] , {1, . . . ,M}, denote by xm ∈ Rp
a patient-specific feature vector that includes the patient characteristics (e.g., gender, age, race, and
Body Mass Index (BMI)) and diagnosis history. Our goal is to predict the future outcome ym under
treatmentm. Assume the following nonlinear regression model:
ym = x
′
mβ
∗
m + hm(xm) + ǫm,
where prime denotes transpose, β∗m is the coefficient vector that captures the linear trend, hm(xm)
describes the nonlinear fluctuation in ym, and ǫm is the noise term with zero mean and standard
deviation ηm that expresses the intrinsic randomness of ym and is assumed to be independent of
xm.
We follow the robust predictive procedure proposed in [5] to estimate the linear coefficient β∗m. It
reduces to solving the following regularized LAD problem:
inf
βm
1
Nm
Nm∑
i=1
|ymi − x′miβm|+ rm‖(−βm, 1)‖2, (1)
where (xmi, ymi), i ∈ [Nm], are the feature-outcome vectors of patients who receive treatment m,
and rm is a regularization penalty. Solving (1) gives us a robust estimator of β
∗
m, which we denote
by βˆm. It measures the relative significance of the features in terms of their relevance to ym, and will
be used to identify the nearest neighbors in the nonlinear non-parametric K-NN regression model.
Specifically, we consider the following weighted distance metric,
‖x− xmi‖2
Wˆm
= (x− xmi)′Wˆm(x− xmi), (2)
where Wˆm is a diagonal matrix with diagonal elements (βˆm1)
2, . . . , (βˆmp)
2, where βˆmi is the i-th
element of βˆm. Given a patient with features x, we find herKm nearest neighbors using (2) within
each treatment groupm. The predicted future outcome for x if treatment m is prescribed, denoted
by yˆm(x), is computed as the average outcome among theKm nearest neighbors, i.e.,
yˆm(x) =
1
Km
Km∑
i=1
ym(i), (3)
where ym(i) is the outcome of the i-th nearest neighbor to x. (3) can be viewed as a local smooth
estimator in the neighborhood of x. The selected neighbors are similar to x in the features that are
predictive of the outcome.
Next consider a randomized policy that prescribes treatment m with probability
e−ξyˆm(x)/
∑M
j=1 e
−ξyˆj(x), with ξ some pre-specified positive scalar. Theorem 2.1 character-
izes the expected true outcome under this policy.
Theorem 2.1. Given any fixed predictor x ∈ Rp, denote its predicted and true future outcome under
treatment m by yˆm(x) and ym(x), respectively. Assume that we adopt a randomized strategy that
prescribes treatmentm with probability e−ξyˆm(x)/
∑M
j=1 e
−ξyˆj(x), for some ξ ≥ 0. Assume yˆm(x)
2
and ym(x) are non-negative, ∀m ∈ [M ]. The expected true outcome under this policy satisfies:
M∑
m=1
e−ξyˆm(x)∑
j e
−ξyˆj(x)
ym(x) ≤ yk(x) +
(
yˆk(x)− 1
M
M∑
m=1
yˆm(x)
)
+ ξ
(
1
M
M∑
m=1
yˆ2m(x) +
M∑
m=1
e−ξyˆm(x)∑
j e
−ξyˆj(x)
y2m(x)
)
+
logM
ξ
,
(4)
for any k ∈ [M ].
Theorem 2.1 says that the expected true outcome of the randomized policy is no worse than the true
outcome of any treatment k plus two components, one accounting for the gap between the predicted
outcome under k and the average predicted outcome, and the other depending on the parameter ξ.
Thinking about choosing k = argminm ym(x), if yˆk(x) is below the average predicted outcome
(which should be true if we have an accurate prediction), it follows from (4) that the randomized
policy leads to a nearly optimal future outcome by an appropriate choice of ξ.
In consideration of the health care costs and treatment transients, it is not desired to switch patients’
treatments too frequently. We thus set a threshold level for the expected improvement on the out-
come, below which the randomized strategy will be frozen and the current therapy will be continued.
Specifically,
mf(x) =
{
m, w.p. e
−ξyˆm(x)
∑
M
j=1 e
−ξyˆj (x)
, if
∑
k
e−ξyˆk(x)
∑
j
e
−ξyˆj (x)
yˆk(x) ≤ xco − T (x),
mc(x), otherwise,
where mf(x) and mc(x) are the future and current treatments of patient x, respectively; xco repre-
sents the current observed outcome, which is assumed to be one of the components of x, and T (x)
is some threshold level which is determined in Theorem 2.2.
Theorem 2.2. Assume that the distribution of the predicted outcome yˆm(x) conditional on x, is
sub-Gaussian, and its ψ2-norm is equal to
√
2Cm(x), for any m ∈ [M ] and any x. Given a small
0 < ǫ¯ < 1, if
P
(∑
k
e−ξyˆk(x)∑
j e
−ξyˆj(x)
yˆk(x) > xco − T (x)
)
≤ ǫ¯,
then,
T (x) = max
(
0, min
m
(
xco − µyˆm(x) −
√
−2C2m(x) log(ǫ¯/M)
))
,
where µyˆm(x) = E[yˆm(x)|x].
Notice that as ξ → ∞, the randomized policy will assign probability 1 to the treatment with the
lowest predicted outcome, which is equivalent to the deterministic policy used in [3]. In this case,
slight modification to the threshold level T (x) is given as follows:
T (x) = max
(
0, min
m
(
xco − µyˆm(x)−
√
−2C2m(x) log ǫ¯
))
.
3 Results
We apply our method to develop optimal prescriptions for patients with type-2 diabetes and/or hyper-
tension. The data used for the study come from the Boston Medical Center – the largest safety-net
hospital in New England – and consist of EHRs containing the patients’ medical history in the
period 1999–2014. We consider the following sets of features for building the predictive model:
(i) demographic information, including gender, age and race; (ii) measurements, including systolic
blood pressure and diastolic blood pressure, Body Mass Index (BMI) and heart rate; (iii) lab tests,
including blood chemistry tests and hematology tests, and (iv) diagnosis history. For the diabetic
patients, we consider both oral, e.g., metformin, pioglitazone, and sitagliptin, etc., and injectable
prescriptions, e.g., insulin. A complete list of the oral prescriptions can be found in the Appendix.
For the hypertension patients, six types of prescriptions are considered: ACE inhibitor, Angiotensin
Receptor Blockers (ARB), calcium channel blockers, thiazide and thiazide-like diuretics, α-blockers
and β-blockers.
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The diabetes dataset contains 12,016 patient visits with 63 normalized features, and the hypertension
dataset contains 26,128 patient visits with the same set of features. We randomly split both datasets
into a training (80%) and a test set (20%), where the training set is used to tune the parameters (e.g.,
the ℓ2 regularizer rm, the number of neighbors Km, and the exponent ξ in the randomized policy)
and train the models, and the test set is used to evaluate the performance. We regress the tunedKm
against
√
Nm and use the derived linear equation to determine the number of neighbors to be used.
We will compare our method with several alternatives that replace our predictive model, which we re-
fer to as RLAD+K-NN, with a different learning procedure such as LASSO, CART, and OLS+KNN
[3]. Both deterministic and randomized prescriptive policies are considered using predictions from
these models. To evaluate the performance, we need to determine the effects of the counterfactual
treatments. By assessing the predictive power of several models on the non-grouped datasets in
terms of their R2 and out-of-sample estimation errors (see Appendix), we choose the RLAD+K-NN
model that excels in all metrics to impute the outcome for an unobservable treatmentm, where the
number of neighbors should be selected to fit the size of the test set.
The average improvement in outcomes (the predicted future outcome under the recommended ther-
apy minus the current observed outcome) on the test set is shown in Table 1, where the numbers
outside the parentheses are the mean values over 5 repetitions, and the numbers in the parentheses
are the corresponding standard deviations. We note that HbA1c is measured in percentage while
systolic blood pressure in mmHg. We also list the results from the standard of care, and the cur-
rent prescription which prescribesmf(x) = mc(x) with probability one, i.e., always continuing the
current drug regimen.
Table 1: The reduction in HbA1c/systolic blood pressure for various models.
Diabetes Hypertension
Deterministic Randomized Deterministic Randomized
LASSO -0.51 (0.16) -0.51 (0.16) -4.71 (1.09) -4.72 (1.10)
CART -0.45 (0.13) -0.42 (0.14) -4.84 (0.62) -4.87 (0.66)
OLS+K-NN -0.53 (0.13) -0.53 (0.13) -4.33 (0.46) -4.33 (0.47)
RLAD+K-NN -0.56 (0.06) -0.55 (0.08) -6.98 (0.86) -7.22 (0.82)
Current prescription -0.22 (0.04) -2.52 (0.19)
Standard of care -0.22 (0.03) -2.37 (0.11)
Several observations are in order: (i) all models outperform the current prescription and the standard
of care; (ii) the RLAD+K-NN model leads to the largest reduction in outcomes with a relatively sta-
ble performance; and (iii) the randomized policy achieves a similar performance (slightly better on
the hypertension dataset) to the deterministic one. We expect the randomized strategy to win when
the effects of several treatments do not differ much, in which case the deterministic algorithm might
produce misleading results. The randomized policy could potentially improve the out-of-sample
(generalization) performance, as it gives the flexibility of exploring options that are suboptimal on
the training set, but might be optimal on the test set. The advantages of the RLAD+K-NN model are
more prominent on the hypertension dataset due to the fact that we considered a finer classification
of the prescriptions for patients with hypertension, while for diabetic patients, we only distinguish
between the oral and injectable prescriptions.
4 Conclusions
We developed a prediction-based randomized prescriptive algorithm that determines the probability
of prescribing each treatment based on the predictions from an RLAD+K-NN model which takes
into account both the high noise level and the nonlinearity of the data. A deterministic variant was
obtained as a special case of the randomized strategy. Theoretical guarantees on the optimality of
the prescriptive algorithm and a closed-form expression for the threshold level were provided. The
proposed approach was applied to two datasets obtained from the Boston Medical Center: one with
diabetic patients and the other for patients with hypertension, providing numerical evidence for the
superiority of our algorithm in terms of the improvement in outcomes.
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Appendix
Proof of Theorem 2.1
Proof. The proof borrows ideas from Theorem 1.5 in [6]. DefineWm , e
−ξyˆm(x)/
∑M
j=1 e
−ξyˆj(x),
and φ ,
∑M
m=1 e
−ξyˆm(x)e−ξym(x). Then,
φ =
( M∑
j=1
e−ξyˆj(x)
) M∑
m=1
Wme
−ξym(x)
≤
( M∑
j=1
e−ξyˆj(x)
) M∑
m=1
Wm
(
1− ξym(x) + ξ2y2m(x)
)
=
( M∑
j=1
e−ξyˆj(x)
)(
1− ξ
M∑
m=1
Wmym(x) + ξ
2
M∑
m=1
Wmy
2
m(x)
)
≤
( M∑
j=1
e−ξyˆj(x)
)
e−ξ
∑
M
m=1Wmym(x)+ξ
2 ∑M
m=1Wmy
2
m(x),
where the first inequality uses the fact that for x ≥ 0, e−x ≤ 1 − x + x2, and the last inequality is
due to the fact that 1 + x ≤ ex. Next let us examine the sum of exponentials:
M∑
j=1
e−ξyˆj(x) ≤
M∑
j=1
(
1− ξyˆj(x) + ξ2yˆ2j (x)
)
= M
(
1− ξ 1
M
M∑
j=1
yˆj(x) + ξ
2 1
M
M∑
j=1
yˆ2j (x)
)
≤Me−ξ 1M
∑
M
j=1 yˆj(x)+ξ
2 1
M
∑
M
j=1 yˆ
2
j (x).
On the other hand, for any k ∈ [M ],
e−ξyˆk(x)−ξyk(x) ≤ φ ≤Me−ξ 1M
∑M
j=1 yˆj(x)+ξ
2 1
M
∑M
j=1 yˆ
2
j (x)−ξ
∑M
m=1Wmym(x)+ξ
2 ∑M
m=1Wmy
2
m(x).
(5)
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Taking the logarithm on both sides of (5) and dividing by ξ, we obtain
1
M
M∑
m=1
yˆm(x) +
M∑
m=1
e−ξyˆm(x)∑
j e
−ξyˆj(x)
ym(x) ≤ yˆk(x) + yk(x)
+ ξ
(
1
M
M∑
m=1
yˆ2m(x) +
M∑
m=1
e−ξyˆm(x)∑
j e
−ξyˆj(x)
y2m(x)
)
+
logM
ξ
.
Proof of Theorem 2.2
Proof. We first review the definition of sub-Gaussian random variables.
Definition 1 (Sub-Gaussian random variable). A random variable y ∈ R with mean µy , E(y) is
sub-Gaussian if there exists some positive constant C such that the tail of y satisfies:
P(|y − µy| ≥ t) ≤ 2 exp(−t2/(2C2)), ∀t ≥ 0. (6)
The smallest constant
√
2C satisfying (6) is called the sub-Gaussian norm, or the ψ2-norm of y,
denoted as |||y|||ψ2 .
By the sub-Gaussian assumption we have:
P
(∑
k
e−ξyˆk(x)∑
j e
−ξyˆj(x)
yˆk(x) > xco − T (x)
)
≤ P
(
max
k
yˆk(x) > xco − T (x)
)
= P
(⋃
k
{
yˆk(x) > xco − T (x)
})
≤
∑
k
P
(
yˆk(x) > xco − T (x)
)
≤
∑
k
exp
(
−
(
xco − T (x)− µyˆk(x)
)2
2C2k(x)
)
,
(7)
where µyˆk(x) = E[yˆk(x)|x]. Note that the probability in (7) is taken with respect to the measure of
the training samples. We essentially want to find the largest threshold T (x) such that the probability
of the expected improvement being less than T (x) is small. Given a small 0 < ǫ¯ < 1, if
P
(∑
k
e−ξyˆk(x)∑
j e
−ξyˆj(x)
yˆk(x) > xco − T (x)
)
≤ ǫ¯,
then from (7), we get: ∑
k
exp
(
−
(
xco − T (x)− µyˆk(x)
)2
2C2k(x)
)
≤ ǫ¯. (8)
A relaxation of (8) implies that:
exp
(
−
(
xco − T (x)− µyˆm(x)
)2
2C2m(x)
)
≤ ǫ¯
M
, ∀m,
which yields that,
T (x) ≤ xco − µyˆm(x)−
√
−2C2m(x) log(ǫ¯/M), ∀m.
Given that T (x) is non-negative, we take:
T (x) = max
(
0, min
m
(
xco − µyˆm(x) −
√
−2C2m(x) log(ǫ¯/M)
))
.
The parameters µyˆm(x) and Cm(x) form = 1, . . . ,M can be estimated through Algorithm 1.
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If using the deterministic policy (ξ →∞),
P(min
m
yˆm(x) > xco − T (x)) = P
(⋂
m
{
yˆm(x) > xco − T (x)
})
≤ P(yˆm(x) > xco − T (x))
≤ exp
(
−
(
xco − T (x)− µyˆm(x)
)2
2C2m(x)
)
, ∀m.
(9)
Similarly, to make
P
(
min
m
yˆm(x) > xco − T (x)
) ≤ ǫ¯,
we take
T (x) = max
(
0, min
m
(
xco − µyˆm(x)−
√
−2C2m(x) log ǫ¯
))
.
Algorithm 1 Estimating the conditional mean µyˆm(x) and standard deviation Cm(x) of the pre-
dicted outcome.
1: Input: a feature vector x; am: the number of subsamples used to compute βˆm, am < Nm; dm:
the number of repetitions.
2: for i = 1, . . . , dm do
3: Randomly pick am samples from prescription group m, and use them to estimate a robust
regression coefficient βˆmi through solving (1).
4: The future outcome for x under prescriptionm is predicted as yˆmi(x) = x
′βˆmi .
5: end for
6: Estimate the conditional mean of yˆm(x) as:
µyˆm(x) =
1
dm
dm∑
i=1
yˆmi(x),
and the conditional standard deviation as:
Cm(x) =
√√√√ 1
dm − 1
dm∑
i=1
(
yˆmi(x)− µyˆm(x)
)2
.
Predictive Performance of Various Models We use four metrics to evaluate the predictive power
of various models on the test set:
• The R-square:
R2(y, yˆ) = 1−
∑Nt
i=1(yi − yˆi)2∑Nt
i=1(yi − y¯)2
,
where y = (y1, . . . , yNt) and yˆ = (yˆ1, . . . , yˆNt) are the vectors of the true (observed) and
predicted outcomes, respectively, with Nt the size of the test set, and y¯ = (1/Nt)
∑Nt
i=1 yi.
• TheMean Squared Error (MSE):
MSE(y, yˆ) =
1
Nt
Nt∑
i=1
(yi − yˆi)2.
• TheMean Absolute Error (MeanAE) that is more robust to large deviations than the MSE in
that the absolute value function increases more slowly than the square function over large
(absolute) values of the argument.
MeanAE(y, yˆ) =
1
Nt
Nt∑
i=1
|yi − yˆi|.
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• The MedianAE which can be viewed as a robust measure of the MeanAE, computing the
median of the absolute deviations:
MedianAE(y, yˆ) = Median (|yi − yˆi|, i = 1, . . . , Nt) .
The out-of-sample performance metrics of the various models on the two datasets are shown in
Tables 2 and 3, where the numbers in the parentheses show the improvement of RLAD+K-NN
compared against other methods. Huber refers to the robust regression method proposed in [8, 9],
and CART refers to the Classification And Regression Trees. Huber/OLS/LASSO + K-NN means
fitting a K-NN regression model with a Huber/OLS/LASSO-weighted distance metric. We note that
in order to produce well-defined and meaningful predictive performance metrics, the datasets used
to generate Tables 2 and 3 did not group the patients by their prescriptions. A universal model
was fit to all patients using the prescription as one of the predictors. Nevertheless, it would still
be considered as a fair comparison as all models were evaluated on the same dataset. The results
provide supporting evidence for the validity of our RLAD+K-NN model that outperforms all others
in all metrics, and is thus used for predicting the outcomes of counterfactual treatments.
Table 2: Performance of different models for predicting future HbA1c for diabetic patients.
Methods R2 MSE MeanAE MedianAE
OLS 0.52 (2%) 1.36 (2%) 0.81 (4%) 0.55 (11%)
LASSO 0.52 (2%) 1.37 (2%) 0.80 (3%) 0.54 (9%)
Huber 0.36 (47%) 1.81 (26%) 0.96 (19%) 0.70 (30%)
RLAD 0.50 (4%) 1.40 (4%) 0.78 (1%) 0.50 (1%)
K-NN 0.25 (109%) 2.11 (37%) 1.07 (27%) 0.81 (39%)
OLS+K-NN 0.52 (0%) 1.34 (0%) 0.79 (1%) 0.51 (3%)
LASSO+K-NN 0.52 (1%) 1.36 (1%) 0.79 (1%) 0.50 (1%)
Huber+K-NN 0.51 (3%) 1.38 (3%) 0.81 (3%) 0.53 (7%)
RLAD+K-NN 0.52 (N/A) 1.34 (N/A) 0.78 (N/A) 0.49 (N/A)
CART 0.49 (7%) 1.43 (7%) 0.81 (3%) 0.50 (2%)
Table 3: Performance of different models for predicting future systolic blood pressure for hyperten-
sion patients.
Methods R2 MSE MeanAE MedianAE
OLS 0.31 (14%) 170.80 (6%) 10.09 (7%) 8.15 (9%)
LASSO 0.31 (14%) 170.83 (6%) 10.08 (7%) 8.22 (10%)
Huber 0.22 (62%) 193.54 (17%) 10.70 (12%) 8.61 (14%)
RLAD 0.30 (18%) 173.32 (8%) 10.11 (7%) 8.28 (11%)
K-NN 0.33 (10%) 167.41 (5%) 9.62 (2%) 7.50 (2%)
OLS+K-NN 0.35 (1%) 160.22 (0%) 9.42 (0%) 7.49 (1%)
LASSO+K-NN 0.32 (12%) 169.50 (6%) 9.74 (3%) 7.73 (5%)
Huber+K-NN 0.32 (10%) 167.92 (5%) 9.71 (3%) 7.84 (6%)
RLAD+K-NN 0.36 (N/A) 159.74 (N/A) 9.42 (N/A) 7.38 (N/A)
CART 0.25 (43%) 186.23 (14%) 10.34 (9%) 8.22 (10%)
Oral prescriptions for diabetes. Acarbose, acetohexamide, chlorpropamide, glimepiride, glip-
izide, glyburide, hydrochloride, metformin, miglitol, nateglinide, pioglitazone, repaglinide, rosigli-
tazone, sitagliptin, tolazamide, tolbutamide, and troglitazone.
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Table 4: Feature importance from the RLAD model for the diabetes dataset.
Features Regression coefficients
lab test: HbA1c 1.02
lab test: blood glucose 0.27
measurement: systolic blood pressure 0.07
prescription: injectable 0.05
lab test: hematocrit 0.04
lab test: hemoglobin -0.03
lab test: sodium 0.03
lab test: platelet count 0.03
diagnosis: retinal disorders 0.02
lab test: leukocyte count 0.02
diagnosis: inflammatory and toxic neuropathy 0.02
lab test: mean corpuscular volume -0.02
lab test: calcium 0.01
lab test: potassium 0.01
diagnosis: disorders of lipoid metabolism 0.01
diagnosis: other disorders of soft tissues 0.01
race: Caucasian -0.01
diagnosis: obesity -0.01
age -0.01
diagnosis: essential hypertension 0.01
Table 5: Feature importance from the RLAD model for the hypertension dataset.
Features Regression coefficients
measurement: systolic blood pressure 7.62
age 1.87
lab test: sodium 1.29
lab test: hemoglobin 1.26
prescription: calcium channel blockers 0.98
lab test: blood glucose 0.93
lab test: hematocrit -0.82
sex: female 0.76
lab:mean corpuscular volume -0.61
diagnosis: asthma -0.61
prescription: ARB 0.57
diagnosis: cataract 0.57
diagnosis: chronic ischemic heart disease -0.56
lab test: potassium 0.55
diagnosis: heart failure -0.53
prescription: diuretics 0.53
diagnosis: cardiac dysrhythmias -0.51
diagnosis obesity 0.46
race: Caucasian -0.46
diagnosis: disorders of fluid electrolyte and acid-base balance 0.45
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